# Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ken Kato,Byoung Chul Cho,Masanobu Takahashi,Morihito Okada,Chen-Yuan Lin,Keisho Chìn,Shigenori Kadowaki,Myung‐Ju Ahn,Yasuo Hamamoto,Yuichiro� Doki,Chueh‐Chuan Yen,Yutaro Kubota,Sung‐Bae Kim,Chih‐Hung Hsu,Eva Holtved,Ioannis Xynos,Mamoru Kodani,Yuko Kitagawa |
| Citations | 1,250 |
| DOI | 10.1016/s1470-2045(19)30626-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173384 |
| OpenAlex ID | https://openalex.org/W2976652879 |
| PMID | 31582355 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Myung‐Ju Ahn](https://scholariq.org/researchers/myung-ju-ahn/)
- [Yuichiro� Doki](https://scholariq.org/researchers/yuichiro-doki/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.